NCT02315066

Brief Summary

To assess the safety and tolerability at increasing dose levels of PF-04518600 alone or in combination wtih PF-05082566 in patients with select advanced or metastatic carcinoma in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
174

participants targeted

Target at P75+ for phase_1

Timeline
Completed

Started Apr 2015

Longer than P75 for phase_1

Geographic Reach
4 countries

30 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 4, 2014

Completed
7 days until next milestone

First Posted

Study publicly available on registry

December 11, 2014

Completed
4 months until next milestone

Study Start

First participant enrolled

April 23, 2015

Completed
5.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 12, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 12, 2020

Completed
1.4 years until next milestone

Results Posted

Study results publicly available

April 21, 2022

Completed
Last Updated

April 21, 2022

Status Verified

February 1, 2022

Enrollment Period

5.6 years

First QC Date

December 4, 2014

Results QC Date

November 10, 2021

Last Update Submit

February 18, 2022

Conditions

Keywords

ImmunotherapyPF-04518600PF-05082566solid tumorstumorsneoplasm metastasisPhase 1hepatocellular carcinomaHCCliver cancerocular melanomamelanomaclear cell renal cell carcinomaRCCkidney cancerhead and neck squamous cell carcinomaHNSCChead and neck cancercervical cancercancer of the cervixgastric cancerstomach cancernon small cell lung cancerNSCLClung cancerurothelial bladder carcinomabladder cancerOX404-1BB

Outcome Measures

Primary Outcomes (6)

  • Number of Participants With Dose Limiting Toxicities (DLTs) in Part A1

    DLT was defined as any of the following adverse events occurring in the first two cycle of treatment (28 days), unless there was a clear alternative explanation: hematologic: grade 4 neutropenia lasting \>7 days, febrile neutropenia; grade ≥3 neutropenic infection; grade ≥3 thrombocytopenia with clinically significant bleeding or requiring medical intervention; grade 4 thrombocytopenia; grade 4 anemia; grade ≥3 anemia related to hemolysis or autoimmune disease. non hematologic: grade ≥3 toxicities that were considered clinically significant, including cytokine release syndrome, infusion reactions and allergic reactions, except those that had not been maximally treated or could be easily treated. The severity of adverse events was graded as per common terminology criteria for adverse events(CTCAE) version 4.03, and there were no DLTs reported.

    The first 2 cycles of treatment (Day 1 up to Day 28)

  • Number of Participants With All-Causality Treatment Emergent Adverse Events(TEAEs) and Serious Adverse Event(SAEs), Treatment-Related TEAEs and SAEs in Part A

    Adverse event (AE) was graded by the investigator according to CTCAE version 4.03 and coded using the Medical Dictionary for Regulatory Activities (MedDRA): Grade 3 (Severe) events=unacceptable or intolerable events. Grade 4 (Life-threatening) events caused participant to be in imminent danger of death. Grade 5 (Death) events=death related to an AE. Treatment-emergent events=between first dose of study drug and up to 35 days after last dose that were absent before treatment or that worsened relative to pretreatment state. TEAEs were defined as those with initial onset or increasing in severity after the first dose of study medication. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

    AEs: The informed consent date up to the last dosing date + 28 days or all drug-related toxicities resolved date. SAEs: The informed consent date through first dosing date + 98 days or up to the last dosing date + 60 days, and any post-reporting period.

  • Number of Participants With Laboratory Test Abnormalities in Part A

    Following parameters were analyzed for laboratory examination: hematology (hemoglobin, hematocrit, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes, partial thromboplastin time (PTT), Prothrombin (PT), PT international ratio); liver function (aspartate aminotransferase(AST), alanine aminotransferase(ALT), total bilirubin, gamma-glutamyl transpeptidase(GT), alkaline phosphatase, albumin, total protein); renal function (blood urea nitrogen, creatinine, uric acid); electrolytes (sodium, potassium, chloride, calcium , phosphate, magnesium); clinical chemistry (glucose, creatine kinase, thyroxine (T4), thyroid stimulating hormone(TSH)), Amylase, Lipase), urinalysis (dipstick \[protein, blood\], microscopy \[urine red blood cell (RBC), white blood cell (WBC), Epithelial Cells\], miscellaneous \[urine casts and bacteria\]).

    The first dosing date to the earlier date between the last dosing date + 35 days and the first new anti-cancer therapy date (if applicable)

  • Number of Participants With DLTs in Part B1

    DLT was defined as any of the following adverse events occurring in the first two cycle of treatment (28 days), unless there was a clear alternative explanation: hematologic: grade 4 neutropenia lasting \>7 days, febrile neutropenia; grade ≥3 neutropenic infection; grade ≥3 thrombocytopenia with clinically significant bleeding or requiring medical intervention; grade 4 thrombocytopenia; grade 4 anemia; grade ≥3 anemia related to hemolysis or autoimmune disease. non hematologic: grade ≥3 toxicities that were considered clinically significant, including cytokine release syndrome, infusion reactions and allergic reactions, except those that had not been maximally treated or could be easily treated. The severity of adverse events was graded as per common terminology criteria for adverse events(CTCAE) version 4.03, and there were no DLTs reported.

    The First 2 Cycles of Treatment (Day 1 up to Day 28)

  • Number of Participants With All-causality TEAEs and SAEs, and Treatment-Related TEAEs and SAEs in Part B

    Adverse event (AE) was graded by the investigator according to CTCAE version 4.03 and coded using the Medical Dictionary for Regulatory Activities (MedDRA): Grade 3 (Severe) events=unacceptable or intolerable events. Grade 4 (Life-threatening) events caused participant to be in imminent danger of death. Grade 5 (Death) events=death related to an AE. Treatment-emergent events=between first dose of study drug and up to 35 days after last dose that were absent before treatment or that worsened relative to pretreatment state. TEAEs were defined as those with initial onset or increasing in severity after the first dose of study medication. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

    AEs: The informed consent date up to the last dosing date + 60 days or all drug-related toxicities resolved date. SAEs: The informed consent date through first dosing date + 98 days or up to the last dosing date + 60 days, and any post-reporting period.

  • Number of Participants With Laboratory Test Abnormalities in Part B

    Following parameters were analyzed for laboratory examination: hematology (hemoglobin, hematocrit, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes, partial thromboplastin time (PTT), Prothrombin (PT), PT international ratio); liver function (aspartate aminotransferase(AST), alanine aminotransferase(ALT), total bilirubin, gamma-glutamyl transpeptidase(GT), alkaline phosphatase, albumin, total protein); renal function (blood urea nitrogen, creatinine, uric acid); electrolytes (sodium, potassium, chloride, calcium , phosphate, magnesium); clinical chemistry (glucose, creatine kinase, thyroxine (T4), thyroid stimulating hormone(TSH)), Amylase, Lipase), urinalysis (dipstick \[protein, blood\], microscopy \[urine red blood cell (RBC), white blood cell (WBC), Epithelial Cells\], miscellaneous \[urine casts and bacteria\]).

    The first dosing date to the earlier date between the last dosing date + 35 days and the first new anti-cancer therapy date (if applicable)

Secondary Outcomes (45)

  • Objective Response Rate (ORR) Assessed by Response Evaluation Criteria in Solid Tumor (RECIST) Version 1.1 and Immune Related Response Evaluation Criteria in Solid Tumors (irRECIST) in Part A

    Baseline up to 24 months post first dose.

  • Kaplan-Meier Estimate of Median Progression-Free Survival (PFS) in Part A

    Baseline up to 24 months post first dose

  • Kaplan-Meier Estimate of Median Time to Progression (TTP) in Part A

    Baseline up to 24 months post first dose

  • Number of Participants Having Stable Disease (SD) in Part A

    Baseline up to 24 months post first dose.

  • Kaplan-Meier Estimate of Median Duration of Response (DoR) in Part A

    Baseline up to 24 months post first dose.

  • +40 more secondary outcomes

Study Arms (2)

PF-04518600

EXPERIMENTAL

OX40 agonist

Drug: PF-04518600

PF-04518600 plus PF-05082566

EXPERIMENTAL

OX40 (CD134) agonist plus 4-1BB (CD137) agonist

Drug: PF-04518600 plus PF-05082566

Interventions

Part A1 - PF-04518600 will be administered intravenously every 14 days in cohorts of 2 or more patients starting at a dose of 0.01 mg/kg. Increases in dose will continue until MTD is determined

PF-04518600

Part B1 -In cohorts of 2 or more patients, PF-04518600 will be administered intravenously every 2 weeks starting at a dose of 0.1 mg/kg and PF-05082566 will be administered intravenously 4 weeks starting at a dose of 20 mg. Increases in dose will continue until MTD is determined.

PF-04518600 plus PF-05082566

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Part A1 only: Patients with histological or cytological diagnosis of HNSCC, HCC, melanoma, or clear cell RCC who progressed on or are intolerant to standard therapy, for which no standard therapy is available or who decline standard therapy.
  • Part A2 only: Patients with histological or cytological diagnosis of advanced/metastatic HCC who are treatment naïve and have declined standard of care, or have had at least 1 prior line of systemic therapy. Prior anti PD L1/PD 1 therapy is allowed.
  • Part B1 only: Patients with histological or cytological diagnosis of NSCLC, HNSCC, melanoma, urothelial bladder carcinoma (including renal pelvis, ureters, urinary bladder, and urethra), gastric or squamous cell carcinoma of the uterine cervix who progressed on or are intolerant to standard therapy, for which no standard therapy is available, or who decline standard therapy.
  • Part B2
  • Arm 1 only:
  • Ocular melanoma patients with advanced/metastatic disease, or
  • Cutaneous/acral melanoma patients with advanced/metastatic disease who have received checkpoint inhibitor (anti PD L1, anti PD 1, or anti CTLA4) based treatment on which disease progressed. \[Note: Checkpoint inhibitor may have been part of a combination therapy, as long as the combination did not contain OX40 or 4 1BB agonist.\] Any questions on prior treatment may be discussed with the Sponsor.
  • Arm 2 only:
  • Histological or cytological diagnosis of NSCLC with advanced/metastatic disease. Patients must have previously received prior anti PD L1 or anti PD 1 mAb on which disease progressed. \[Note: Previous anti PD L1 or anti PD 1 mAb may have been part of a combination therapy, eg, in combination with chemotherapy, as long as the combination did not contain OX40 or 4 1BB agonist.\]
  • Performance Status of 0 or 1 - Adequate bone marrow, kidney and liver function

You may not qualify if:

  • Brain metastases requiring steroids
  • Major surgery, Radiation therapy within 4 weeks of starting study treatment (except: palliative radiotherapy to a limited field is allowed after consultation with sponsor's medical monitor at any time during study participation, including during screening), or systemic anti-cancer therapy within 4 weeks of study treatment start (6 weeks for mitomycin C or nitrosoureas)
  • Active and clinically significant bacterial, fungal, or viral infection
  • History of active autoimmune disorders
  • History of immune-mediated adverse events requiring immunosuppressive therapy or were grade 3 or higher related to prior immune-modulatory therapy
  • Prior treatment with an OX40 agonist and 4-1BB agonist (for Part B1/B2)
  • Prior anthracycline treatment and at risk of cardiac failure (New York Heart Association Class 2)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (30)

The Angeles Clinic And Research Institute, A Cedars-Sinai Affiliate

Los Angeles, California, 90025, United States

Location

Keck Hospital of USC

Los Angeles, California, 90033, United States

Location

LAC+USC Medical Center

Los Angeles, California, 90033, United States

Location

USC/Norris Comprehensive Cancer Center

Los Angeles, California, 90033, United States

Location

Ronald Regan Medical Center

Los Angeles, California, 90095, United States

Location

UCLA Hematology & Oncology Clinic

Los Angeles, California, 90095, United States

Location

Hoag Memorial Hospital Presbyterian

Newport Beach, California, 92663, United States

Location

Medical Imaging Center of Southern California, Inc.

Santa Monica, California, 90403, United States

Location

Santa Monica UCLA Hematology & Oncology Clinic

Santa Monica, California, 90404, United States

Location

UConn Health, Pharmacy

Farmington, Connecticut, 06030-2205, United States

Location

UConn Health, Neag Comprehensive Cancer Center

Farmington, Connecticut, 06030, United States

Location

H. Lee Moffitt Cancer Center & Research Institute

Tampa, Florida, 33612, United States

Location

Massachusetts General Hospital (MGH)

Boston, Massachusetts, 02114, United States

Location

Brigham & Women's Hospital (BWH)

Boston, Massachusetts, 02115, United States

Location

Beth Israel Deaconess Medical Center (BIDMC)

Boston, Massachusetts, 02215, United States

Location

Dana-Farber Cancer Institute (DFCI)

Boston, Massachusetts, 02215, United States

Location

Massachusetts General/Chelsea HealthCare Center

Chelsea, Massachusetts, 02150, United States

Location

Mass General/North Shore Center for Outpatient Care

Danvers, Massachusetts, 01923, United States

Location

Mass General West

Waltham, Massachusetts, 02451, United States

Location

Columbia University Medical Center - Herbert Irving Pavilion

New York, New York, 10032, United States

Location

Methodist Hospital-Pathology

Houston, Texas, 77030, United States

Location

The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States

Location

Seattle Cancer Care Alliance

Seattle, Washington, 98109, United States

Location

University of Washington Medical Center

Seattle, Washington, 98195, United States

Location

Groupe hospitalier Pitie Salpetriere

Paris, 75013, France

Location

Institut Gustave Roussy

Villejuif, 94805, France

Location

National Cancer Center Hospital East

Kashiwa, Chiba, 277-8577, Japan

Location

The Netherlands Cancer Institute

Amsterdam, 1066 CX, Netherlands

Location

Slotervaart Hospital/Antoni van Leeuwenhoek

Amsterdam, 1066 EC, Netherlands

Location

Erasmus MC

Rotterdam, 3015 GD, Netherlands

Location

Related Publications (2)

  • Hamid O, Chiappori AA, Thompson JA, Doi T, Hu-Lieskovan S, Eskens FALM, Ros W, Diab A, Spano JP, Rizvi NA, Wasser JS, Angevin E, Ott PA, Forgie A, Yang W, Guo C, Chou J, El-Khoueiry AB. First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors. J Immunother Cancer. 2022 Oct;10(10):e005471. doi: 10.1136/jitc-2022-005471.

  • Diab A, Hamid O, Thompson JA, Ros W, Eskens FALM, Doi T, Hu-Lieskovan S, Klempner SJ, Ganguly B, Fleener C, Wang X, Joh T, Liao K, Salek-Ardakani S, Taylor CT, Chou J, El-Khoueiry AB. A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers. Clin Cancer Res. 2022 Jan 1;28(1):71-83. doi: 10.1158/1078-0432.CCR-21-0845. Epub 2021 Oct 6.

Related Links

MeSH Terms

Conditions

NeoplasmsNeoplasm MetastasisCarcinoma, HepatocellularLiver NeoplasmsUveal MelanomaMelanomaCarcinoma, Renal CellKidney NeoplasmsSquamous Cell Carcinoma of Head and NeckHead and Neck NeoplasmsUterine Cervical NeoplasmsStomach NeoplasmsCarcinoma, Non-Small-Cell LungLung NeoplasmsUrinary Bladder Neoplasms

Interventions

utomilumab

Condition Hierarchy (Ancestors)

Neoplastic ProcessesPathologic ProcessesPathological Conditions, Signs and SymptomsAdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeDigestive System NeoplasmsNeoplasms by SiteDigestive System DiseasesLiver DiseasesNeuroendocrine TumorsNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms, Nerve TissueNevi and MelanomasUveal NeoplasmsEye NeoplasmsEye DiseasesUveal DiseasesSkin NeoplasmsSkin DiseasesSkin and Connective Tissue DiseasesUrologic NeoplasmsUrogenital NeoplasmsFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesKidney DiseasesUrologic DiseasesMale Urogenital DiseasesCarcinoma, Squamous CellUterine NeoplasmsGenital Neoplasms, FemaleUterine Cervical DiseasesUterine DiseasesGenital Diseases, FemaleGenital DiseasesGastrointestinal NeoplasmsGastrointestinal DiseasesStomach DiseasesCarcinoma, BronchogenicBronchial NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsLung DiseasesRespiratory Tract DiseasesUrinary Bladder Diseases

Limitations and Caveats

A decision was made by the sponsor to terminate further enrollment to the study on 03 Oct 2018 due to business reasons. The decision to terminate study enrollment was not based on any safety or regulatory concerns.

Results Point of Contact

Title
Pfizer ClinicalTrials.gov Call Center
Organization
Pfizer, Inc.

Study Officials

  • Pfizer CT.gov Call Center

    Pfizer

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NON RANDOMIZED
Masking
NONE
Masking Details
Open-label
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 4, 2014

First Posted

December 11, 2014

Study Start

April 23, 2015

Primary Completion

November 12, 2020

Study Completion

November 12, 2020

Last Updated

April 21, 2022

Results First Posted

April 21, 2022

Record last verified: 2022-02

Data Sharing

IPD Sharing
Will not share

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.

Locations